ReviewHuman vaccines & immunotherapeutics2022
A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population.
Review in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Pay-it-forward intervention increased pneumococcal vaccine uptake among older adults in China: a randomized controlled trial.BMC medicine · 2026Trial
- Changes in 23-valent pneumococcal polysaccharide vaccination rate and associated factors in 2022 and 2024 among community-based older adults in Shanghai, China.Human vaccines & immunotherapeutics · 2026Article
- Article
- Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China.Infectious medicine · 2026Article
- Real-World Vaccination Data Analysis for Three Vaccines Among Individuals Aged 60 and Older in Shanghai, China.Vaccines · 2026Article
- The impact of empowering community physicians to prescribe vaccines on public vaccination: a grounded theory interview study.Frontiers in public health · 2026Article
- Evaluation of Influenza Vaccine Coverage Levels of People 65 Years and Older by Lot Quality Technique: A Cross-Sectional Study.Florence Nightingale journal of nursing · 2025Article
- Article
- Evaluating the impact of the vaccination prescription program on herpes zoster vaccine coverage in Ningbo, China: An interrupted time series analysis.Human vaccines & immunotherapeutics · 2025Article
- A narrative review on the effectiveness of PPSV23 vaccination in adults in China.Human vaccines & immunotherapeutics · 2025Review
- Closer adult child-parent relations the stronger the vaccine hesitancy: A cross-sectional study of adult Children's attitudes toward pneumococcal vaccination of elderly parents and its determinants in Guangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- Factors associated with willingness to accept pneumococcal vaccine based on the Health Belief Model among the elderly (≥60 years) living in Klang Valley, Malaysia.Human vaccines & immunotherapeutics · 2025Article
- Trends and determinants of 23-valent pneumococcal polysaccharide vaccine revaccination among older adults in Shanghai, China, 2013-2023: A database-based study.Human vaccines & immunotherapeutics · 2025Article
- Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview with Data and Policy Insights from Türkiye.Infectious diseases & clinical microbiology · 2025Review
- Age- and time-dependent waning vaccine effectiveness of PPV23 against community-acquired pneumonia among adults aged 60 and older: A cohort study.Human vaccines & immunotherapeutics · 2025Article
- Understanding the drivers and barriers of elderly vaccination in post-pandemic China: a qualitative study in Shenzhen.BMC public health · 2025Article
- Pay-It-Forward 23-Valent Pneumococcal Polysaccharide Vaccination Among Older Adults: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2025Article
- Article
- Article
- The coverage and challenges of increasing uptake of non-National Immunization Program vaccines in China: a scoping review.Infectious diseases of poverty · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 23-valent pneumococcal polysaccharide vaccine (PPSV-23) is the only approved vaccine for pneumococcal diseases in elderly Chinese population. Though regional studies explored the PPSV-23 vaccination coverage rates and influencing factors in China, a large-scale, nation-wide epidemiological surveillance studies to understand the different factors impeding pneumococcal vaccination rate are required. Hence, this review summarized PPSV-23 coverage rate, analyzed and identified vaccination influencing factors among elderly population across China by exploring articles published in CNKI, Wanfang and PubMed databases. Pneumococcal vaccination coverage rate was found to be low at around 1.23%~42.10% in China. Co-morbidities, knowledge, attitude, perception toward pneumonia and PPSV-23, education level, socio-economic disparities, health education and local policies were some of the factors associated with vaccination willingness among elderly Chinese population. Interventions or policies like government funding, subsidies, inclusion of PPSV-23 in medical insurance, or systematic encouragement from HCPs as key strategies should be implemented to encourage vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.